X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (126) 126
male (92) 92
middle aged (92) 92
female (91) 91
aged (87) 87
melanoma (87) 87
oncology (85) 85
adult (77) 77
melanoma - drug therapy (56) 56
cancer (47) 47
survival (47) 47
metastasis (43) 43
treatment outcome (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
ipilimumab (34) 34
skin neoplasms - drug therapy (32) 32
chemotherapy (31) 31
mutation (31) 31
aged, 80 and over (30) 30
clinical trials (30) 30
melanoma - mortality (29) 29
care and treatment (28) 28
metastases (27) 27
metastatic melanoma (27) 27
prognosis (27) 27
melanoma - pathology (26) 26
neoplasm staging (26) 26
disease-free survival (25) 25
surgery (25) 25
melanoma - genetics (24) 24
therapy (24) 24
antineoplastic combined chemotherapy protocols - adverse effects (23) 23
patients (23) 23
proto-oncogene proteins b-raf - genetics (23) 23
analysis (22) 22
research (22) 22
skin neoplasms - pathology (22) 22
survival analysis (22) 22
vemurafenib (22) 22
dermatology (21) 21
skin neoplasms - mortality (20) 20
young adult (20) 20
adolescent (19) 19
immunotherapy (19) 19
italy (19) 19
retrospective studies (19) 19
survival rate (19) 19
melanoma - secondary (18) 18
risk factors (18) 18
safety (18) 18
follow-up studies (17) 17
time factors (17) 17
abridged index medicus (16) 16
antibodies, monoclonal - adverse effects (16) 16
antineoplastic agents - adverse effects (16) 16
cancer therapies (16) 16
double-blind method (16) 16
esophageal cancer (16) 16
studies (16) 16
antineoplastic agents - therapeutic use (15) 15
skin neoplasms - genetics (15) 15
medicine, general & internal (14) 14
medicine, research & experimental (14) 14
melanoma - surgery (14) 14
antibodies, monoclonal - therapeutic use (13) 13
kaplan-meier estimate (13) 13
skin neoplasms - surgery (13) 13
squamous cell carcinoma (13) 13
carcinoma, squamous cell - drug therapy (12) 12
cisplatin - administration & dosage (12) 12
dabrafenib (12) 12
drug therapy (12) 12
hematology, oncology and palliative medicine (12) 12
medical research (12) 12
nivolumab (12) 12
quality of life (12) 12
trial (12) 12
braf (11) 11
carcinoma, squamous cell - pathology (11) 11
cisplatin (11) 11
cutaneous melanoma (11) 11
disease progression (11) 11
double-blind (11) 11
multicenter (11) 11
open-label (11) 11
patient outcomes (11) 11
tumors (11) 11
antibodies, monoclonal - administration & dosage (10) 10
antineoplastic agents - administration & dosage (10) 10
efficacy (10) 10
esophageal neoplasms - drug therapy (10) 10
esophageal neoplasms - pathology (10) 10
imidazoles - administration & dosage (10) 10
management (10) 10
medical prognosis (10) 10
mek inhibition (10) 10
neoadjuvant therapy (10) 10
oximes - administration & dosage (10) 10
pembrolizumab (10) 10
usage (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 863 - 873
Summary Background Dabrafenib plus trametinib improves clinical outcomes in BRAFV600 -mutant metastatic melanoma without brain metastases; however, the... 
Hematology, Oncology and Palliative Medicine
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 14, pp. 1345 - 1356
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 4, pp. 320 - 330
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 19, pp. 1824 - 1835
Journal Article